Press Releases Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
14.8 ^USD	+0.54%		-5.73%	+38.32%

05-14	Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI
05-14	Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update	05-14	BU
Immunome to Present at 2024 Bank of America Healthcare Conference	05-08	BU
Immunome Appoints Kinney Horn as Chief Business Officer	05-02	BU
Immunome Appoints Sandra M. Swain to Board of Directors	04-25	BU
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting	04-08	AQ
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting	04-05	BU
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets	03-28	BU
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala	03-26	BU
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	03-26	AQ
Immunome to Participate in the Leerink Partners Global Biopharma Conference	03-07	BU
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference	03-04	AQ
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference	03-01	BU
Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	02-21	AQ
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	02-20	BU
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	02-20	AQ
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	02-16	BU
Immunome Announces Pricing of Public Offering of Common Stock	02-14	BU
Immunome Announces Proposed Public Offering of Common Stock	02-13	BU
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	02-06	BU
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	02-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immunome, Inc.

Equities

IMNM

US45257U1088

Press Releases

Filters